ReviewArthritis research & therapy2017
Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.
Review in Arthritis research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- 2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.International journal of rheumatic diseases · 2026Guideline
- Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis.BMC rheumatology · 2025Pooled it
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Arthritis care & research · 2021Guideline
- Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence.Rheumatology international · 2018Pooled it
- Trial
- Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2024Trial
- Trial
- CD11b as a diagnostic biomarker of rheumatoid arthritis and as a risk factor of periodontitis: a pilot study.Odontology · 2026Observational
- First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.Journal of comparative effectiveness research · 2026Article
- Lack of association between rheumatoid factor levels and clinical response to certolizumab pegol in patients with rheumatoid arthritis: an observational study.Drugs in context · 2026Article
- Impact of HLA-DRB1 SE, anti-citrullinated protein antibodies and smoking on radiographic outcome in Greek patients with Rheumatoid Arthritis.BMC rheumatology · 2025Article
- Transitional and CD21BMC rheumatology · 2025Article
- Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions.Rheumatology and therapy · 2025Article
- Metabolomics for Distinguishing Cardiovascular Risk in Rheumatoid Arthritis Across Different Disease-Modifying Antirheumatic Drug Therapies.Journal of clinical medicine research · 2025Article
- Yoga as an adjunctive therapy for rheumatoid arthritis.The Cochrane database of systematic reviews · 2025Article
- Triple positivity for autoantibodies in patients with rheumatoid arthritis is associated with a severe course of the disease but not with bone turnover markers.Reumatologia · 2025Article
- Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update.Rheumatology and immunology research · 2024Article
- On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis.RMD open · 2024Review
- Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study.BMC rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognostic factors are used for treatment decisions in rheumatoid arthritis (RA). High disease activity, the early presence of erosions, and autoantibody positivity are the most frequently used poor prognostic factors but other features, such as functional disability, extraarticular disease, or multibiomarkers, are also assessed. Prognostic factors are incorporated in current treatment recommendations for the management of RA and are used as inclusion criteria in randomized controlled trials. They are defined heterogeneously and the relevance of a single or combined presence of poor prognostic factors remains unclear. This review summarizes the current definitions of poor prognostic factors and their use in clinical research. Perspectives on future research are also outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.